Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

Press/Media

Period	2 Jun 2024

Media coverage

Title	Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Media name/outlet	Ariva.de
Country/Territory	Germany
Date	2/06/24
URL	ct.moreover.com/?a=53956883168&p=1gw&v=1&x=up6bzK4q4msk6KIfDQ8yWQ
Persons	Jin-A Choi